-
Separating Growth Arrest from Cancer Cell Death
2026-09-25
Hannah R. Schwartz’s dissertation highlights a basic but consequential problem in cancer drug testing: relative viability and fractional viability describe different aspects of response and should not be treated as interchangeable. Its central finding—that drugs can affect proliferation and cell death in different proportions and on different timelines—supports pairing complementary measurements when interpreting in vitro drug effects.
-
Direct Mouse Genotyping Kit: Practical PCR Workflow
2026-09-25
The Direct Mouse Genotyping Kit supports genomic DNA release from mouse tissue for PCR without conventional DNA purification, simplifying routine mouse genetic screening. It is intended for PCR-based genotyping workflows; assay-specific cycling conditions and performance must be validated, and the kit should not be treated as a general-purpose DNA purification or quantitative assay system.
-
Ceritinib Combinations in Triple-Negative Breast Cancer
2026-09-24
Dong and colleagues identify ceritinib as a candidate for combination treatment in triple-negative breast cancer (TNBC), with distinct strategies for androgen-receptor-positive and AR-low or AR-negative models. Their preclinical findings support pairing ceritinib with enzalutamide or paclitaxel, while leaving clinical benefit and optimal treatment schedules to be established.
-
Oral Pathogen Proteases Redirect Angiotensin I Processing
2026-09-24
A 2025 study reports that surface-associated PepO metalloproteases from Porphyromonas gingivalis and Tannerella forsythia can hydrolyze angiotensin I in a way that favors angiotensin-(1–7) formation. Enzyme, structural, and bacterial experiments connect periodontal pathogens with local renin–angiotensin system peptide processing, while leaving the consequences for human periodontal or systemic physiology open.
-
Stat3 in Fyn-Driven Dopaminergic Neurodegeneration
2026-09-23
A zebrafish model of neural expression of constitutively active Fyn links dopaminergic neuron loss and microglial activation with Stat3 and NF-κB signaling. The findings identify Stat3 as a downstream contributor to Fyn-associated neurodegeneration and suggest that Stat3 and NF-κB jointly shape the neuronal phenotype, while leaving important questions about disease relevance and pathway timing open.
-
Moxidectin as a Mechanistic Probe in Fungal Research
2026-09-23
Moxidectin is an established macrocyclic lactone anthelmintic with an emerging role as a mechanistic potentiator of polyene antifungals. This article explains how ergosterol-focused evidence can guide assay design while separating approved antiparasitic use from preclinical antifungal research.
-
Mucocutaneous Candidiasis: Diagnosis and Treatment
2026-09-22
This 2009 guideline review organizes the diagnosis and treatment of cutaneous and oral candidiasis around direct microscopy, recognition of predisposing factors, and appropriately selected antifungal therapy. Its practical contribution is a clinically grounded framework that places topical imidazole treatment at the center of superficial disease while defining when culture, histopathology, or systemic therapy is necessary.
-
(S)-(+)-Ibuprofen COX Inhibition Workflows
2026-09-22
Build more interpretable inflammation and pain experiments with enantiopure (S)-(+)-Ibuprofen, from concentration-response COX assays to cell-based prostaglandin measurements. The workflow emphasizes solvent control, stereochemical consistency, orthogonal endpoints, and practical troubleshooting for reproducible nonsteroidal anti-inflammatory drug research.
-
Capsazepine: TRPV1 Antagonist Research Guide
2026-09-21
Capsazepine is a synthetic TRPV1 ion channel antagonist and capsaicin analog used to probe nociception, sensory-neuron signaling, and related channel responses. Supplier-reported benchmarks include competitive inhibition of capsaicin binding, voltage-activated calcium-current blockade, and TRPM8 channel inhibition, while assay selectivity and translational limits require explicit controls.
-
Apicidin: From HDAC Mechanism to Translational Strategy
2026-09-21
Apicidin is a selective histone deacetylase inhibitor that connects chromatin regulation with cancer biology, angiogenesis, and reproductive toxicology. This thought-leadership guide translates its HDAC3/HDAC6 profile into practical assay strategy while defining the evidence boundaries researchers should observe when moving from mechanistic experiments to translational claims.
-
Digoxin as a Mechanism-to-Assay Research Tool
2026-09-20
Digoxin is more than a Na+/K+ ATPase pump inhibitor: it can connect ion transport, hypoxia signaling, inflammation, and fibrosis in research models. This article translates recent thyroid eye disease findings into practical assay-design decisions while defining the limits of cardiovascular and antiviral extrapolation.
-
2-NBDG Glucose Uptake Assay Kit Guide
2026-09-19
The 2-NBDG Glucose Uptake Assay Kit provides non-radioactive fluorescence-based measurement of glucose analogue accumulation in cells. Its 2-NBDG fluorescent glucose analogue, GLUT1 inhibitor control, and 96-well format support glucose metabolism research while requiring careful separation of uptake, viability, glycolysis, and lipid-metabolism readouts.
-
Nigericin: From Ion Transport to Translational Strategy
2026-09-18
Nigericin is a potassium/hydrogen ion carrier that converts membrane ion transport into a controllable perturbation of intracellular pH, mitochondrial homeostasis, and GSDMD-associated cell death. This thought-leadership guide connects mechanistic assay design with translational decision-making while distinguishing product facts from hypotheses that require validation.
-
Moxidectin in Antifungal Synergy Assays
2026-09-18
Moxidectin extends beyond veterinary antiparasitic research as a mechanistically informative potentiator for amphotericin B and nystatin assays. This workflow translates ergosterol biology into reproducible checkerboard, biofilm, molecular, and oral candidiasis model experiments while clearly separating published findings from optimization recommendations.
-
IPR-803: Reframing uPAR Blockade in Oncology
2026-09-17
IPR-803 is a small-molecule urokinase receptor inhibitor that disrupts the uPAR–uPA protein–protein interaction, offering a mechanistically focused approach to tumor invasion, metastasis, angiogenesis, and stromal biology. This article connects structural rationale with breast and pancreatic cancer evidence, practical assay design, and translational decision-making.